Fundamental Analysis of BIOCRYST PHARMACEUTICALS INC(NASDAQ:BCRX) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to BCRX. BCRX was compared to 571 industry peers in the Biotechnology industry. BCRX may be in some trouble as it scores bad on both profitability and health. BCRX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year BCRX has reported negative net income.

In the past year BCRX has reported a negative cash flow from operations.

BCRX had negative earnings in each of the past 5 years.

In the past 5 years BCRX always reported negative operating cash flow.

1.2 Ratios

With a decent Return On Assets value of -25.20%, BCRX is doing good in the industry, outperforming 73.02% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-25.2%
ROE	N/A
ROIC	N/A

ROA(3y)-40.02%

ROA(5y)-47.36%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 98.06%, BCRX belongs to the top of the industry, outperforming 97.53% of the companies in the same industry.

In the last couple of years the Gross Margin of BCRX has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for BCRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	98.06%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y2.92%

GM growth 5Y0.21%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for BCRX has been increased compared to 1 year ago.

The number of shares outstanding for BCRX has been increased compared to 5 years ago.

Compared to 1 year ago, BCRX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -2.75, we must say that BCRX is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -2.75, BCRX is in line with its industry, outperforming 50.26% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-2.75

ROIC/WACCN/A

WACC9.34%

2.3 Liquidity

BCRX has a Current Ratio of 2.78. This indicates that BCRX is financially healthy and has no problem in meeting its short term obligations.

With a Current ratio value of 2.78, BCRX is not doing good in the industry: 67.55% of the companies in the same industry are doing better.

A Quick Ratio of 2.73 indicates that BCRX has no problem at all paying its short term obligations.

BCRX's Quick ratio of 2.73 is on the low side compared to the rest of the industry. BCRX is outperformed by 66.49% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.78
Quick Ratio	2.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.79% over the past year.

Looking at the last year, BCRX shows a very strong growth in Revenue. The Revenue has grown by 29.92%.

BCRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.13% yearly.

EPS 1Y (TTM)46.79%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%63.16%

Revenue 1Y (TTM)29.92%

Revenue growth 3Y165.04%

Revenue growth 5Y74.13%

Sales Q2Q%34.98%

3.2 Future

Based on estimates for the next years, BCRX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.29% on average per year.

The Revenue is expected to grow by 18.51% on average over the next years. This is quite good.

EPS Next Y61.64%

EPS Next 2Y39.37%

EPS Next 3Y31.65%

EPS Next 5Y24.29%

Revenue Next Year36.03%

Revenue Next 2Y27.39%

Revenue Next 3Y23.27%

Revenue Next 5Y18.51%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

BCRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year BCRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as BCRX's earnings are expected to grow with 31.65% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y39.37%

EPS Next 3Y31.65%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for BCRX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOCRYST PHARMACEUTICALS INC

NASDAQ:BCRX (11/22/2024, 8:25:22 PM)

After market: 7.6 0 (0%)

7.6

+0.11 (+1.47%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.57B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-25.2%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	98.06%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.84

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.78
Quick Ratio	2.73
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)46.79%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y61.64%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)29.92%

Revenue growth 3Y165.04%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

BIOCRYST PHARMACEUTICALS INC (BCRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens